What Scope Fluidics does

Scope Fluidics S.A. is a Polish publicly listed biotechnology company that operates a venture-studio model: it originates diagnostic concepts, develops them within wholly-owned special-purpose vehicles, and commercializes them either through strategic transactions with global operators or via distribution agreements. Founded in 2010-2011 and listed on the Main Market of the Warsaw Stock Exchange, the group sits at 101-250 employees and is headquartered in Warsaw. The company's central mission is to address unmet needs in medical diagnostics, with antimicrobial resistance as the primary clinical problem targeted.

The group's lead asset is the BACTEROMIC system, developed by its subsidiary Bacteromic Sp. z o.o. BACTEROMIC is a microfluidic, automated antibiotic susceptibility testing (AST) platform comprising a laboratory analyzer, a cartridge filling device, and single-use panels accommodating up to 60 antibiotics at multiple dilutions, enabling precise Minimum Inhibitory Concentration (MIC) determination and detection of resistance mechanisms such as ESBL. The platform is sold in two certified configurations: the UNI Panel (30 antibiotics, 56 drug-bug combinations, 16-hour result, CE IVDR certified February 2026) and the UNI FAST Panel (24 antibiotics, 48 drug-bug combinations, 6-8 hour result, CE IVDR certified May 2026), with an extended UNI FAST version targeting FDA certification in H1 2027 covering up to 52 antibiotics and 3 resistance mechanisms. Earlier-stage projects include EDOCERA (stroke prevention and diagnostics) and HYBOLIC, both spun out of the Scope Discovery internal pipeline, which has screened 65 concepts to date.

The business model is structured around the SPV-to-exit pathway demonstrated by the August 2022 sale of Curiosity Diagnostics (PCR|ONE molecular diagnostic system) to Bio-Rad for $100 million plus up to $70 million in contingent payments. The company is now preparing BACTEROMIC for a similar strategic transaction, with Perella Weinberg Partners engaged as M&A advisor since October 2025. In parallel, a commercial channel is being built via regional distribution agreements signed in January 2026 with Mefamed (Turkey) and ELTA MR (Romania), and an FDA-track US clinical program initiated in April 2026. Scope Fluidics is capitalized with PLN 138-157 million in cash (as of end-2025 and Q1 2026), supplemented by a Series K share placement in October 2025 raising over PLN 64 million gross and a new European Investment Bank term sheet proposing up to EUR 15 million in three tranches. The company has not yet reported material product revenue.

Name

Scope Fluidics

Legal name

Scope Fluidics S.A.

Website

https://scopefluidics.com

Company type

Public

Founded year

2011

Operating status

Operating

Headcount range

101–250 employees

Short description

Polish biotech that develops microfluidic diagnostic projects within special-purpose vehicles and commercializes them via strategic transactions or distribution; its lead asset, the CE IVDR-certified BACTEROMIC rapid antibiotic susceptibility testing system, targets hospital and clinical laboratories in Europe and the US.

Ownership category

akta.pro rank

Product category

Clinical Microbiology / In-Vitro Diagnostic Devices

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN)

akta.pro secondary industries

Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations) (HLAGAIAD), Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC), Microbiology & Infectious Disease Testing (Trial Support) (HLAGAEAF)

Keywords

• Antibiotic susceptibility testing
• Microfluidic diagnostic systems
• Rapid AST devices
• Antimicrobial resistance diagnostics
• Clinical microbiology instruments

Headquarters

HQ city

Warsaw

HQ country

Poland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. BACTEROMIC System Sales (planned): Revenue will be generated through the sale of BACTEROMIC laboratory analyzers and single-use Panels (cartridges) to hospitals, central and hospital laboratories, and other healthcare facilities. The system consists of an analyzer (and filling device) and consumable single-use Panels, implying a recurring consumables revenue model after initial instrument placement.
2. Strategic Transaction / M&A: Scope Fluidics' business model is structured around developing innovative projects within special-purpose vehicles and selling them to global operators in the medical diagnostics market. The sale of Curiosity Diagnostics to Bio-Rad in August 2022 for $100 million plus up to $70 million in contingency payments (total ~$170 million) demonstrates this model. BACTEROMIC is currently the next project in the pipeline for a strategic transaction, with Perella Weinberg Partners serving as transaction advisor.
3. Licensing and IP: Revenue potential through licensing of proprietary microfluidic technologies and diagnostic methods. The company has built a portfolio of intellectual property rights and patents including European and US patents for BACTEROMIC technology.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Scope Fluidics develops and commercializes innovative medical diagnostic systems based on proprietary microfluidic technologies, with its lead product BACTEROMIC being a rapid, automated Antibiotic Susceptibility Testing (AST) system. The system consists of a laboratory analyzer with a filling device plus single-use panels accommodating up to 60 antibiotics at multiple dilutions to determine Minimum Inhibitory Concentration (MIC). The company operates a venture-studio model, developing projects within special-purpose vehicles (Bacteromic, EDOCERA, HYBOLIC) and commercializing them via strategic transactions or direct distribution to clinical laboratories and hospitals.

Product overview

Scope Fluidics is a biotechnology company developing innovative projects based on microfluidic technologies for medical diagnostics. The company operates through special-purpose vehicles and follows a model of developing innovative projects, then selling to global entities. The core product is the BACTEROMIC system - an automated Antibiotic Susceptibility Testing (AST) platform with modular single-use panels (UNI Panel, UNI FAST Panel, PBC Panel) for rapid antibiotic resistance assessment. Additional projects include EDOCERA (stroke diagnostics) and HYBOLIC, developed through the Scope Discovery venture studio unit. The PCR|ONE system was sold to Bio-Rad in 2022 but was discontinued in December 2025.

Differentiator

Problem solved

Functional benefit

Brands

• BACTEROMIC: Rapid, automated Antibiotic Susceptibility Testing (AST) system for assessing drug susceptibility of microorganisms and identifying synergistic antibiotic pairs
• Scope Discovery
• Scope Fluidics Fellowship
• PCR|ONE

Products and services

• BACTEROMIC System Rapid, automated Antibiotic Susceptibility Testing (AST) system that delivers precise information on which clinically relevant antibiotic will be most effective against a bacterial infection. Consists of a laboratory analyzer, an automatic cartridge filling device, and single-use panels accommodating up to 60 antibiotics at multiple dilutions for precise Minimum Inhibitory Concentration (MIC) determination. Targets hospitals, central and hospital laboratories, and diagnostic facilities.
• BACTEROMIC UNI Panel Single-use cartridge panel covering 30 antibiotics and 56 antibiotic-bacteria (drug-bug) combinations, with ESBL resistance mechanism detection, enabling antibiotic susceptibility assessment within 16 hours. CE IVDR certified in February 2026. Used with the BACTEROMIC analyzer for clinical microbiology laboratories.
• BACTEROMIC UNI FAST Panel Fast single-use cartridge panel covering 24 antibiotics and 48 antibiotic-bacteria combinations, enabling antibiotic susceptibility assessment in 6–8 hours. CE IVDR certified in May 2026. An extended version covering up to 52 antibiotics and 3 resistance mechanisms (ESBL, MR, HLGR) is in development for US FDA certification (planned H1 2027).
• BACTEROMIC PBC Panel Panel in development as part of the BACTEROMIC system portfolio. The product is mentioned alongside UNI FAST and the extended UNI FAST version as a future cartridge configuration for the BACTEROMIC analyzer.
• EDOCERA (DSC001) Special-purpose-vehicle project developing a solution for stroke prevention and diagnostics. Technology has been verified and a device prototype is under development. Targeted for clinical settings where rapid stroke risk assessment and diagnostic information are needed.
• HYBOLIC (DSC027) Special-purpose-vehicle project originating from Scope Discovery, qualified for development within a dedicated project company. Included in Scope Fluidics' expanded financing model allowing external capital raising at earlier stages with key individuals able to acquire equity stakes.

Quantifiable outcome

• Antibiotic susceptibility assessment in 6-8 hours with UNI FAST Panel (vs. 16 hours with UNI Panel)
• +4 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Six partnerships are on record, tiered core.

• US Research Center for FDA Clinical TrialscoreStrategic or Co-development Partner · 21 April 2026In April 2026, the company began cooperation with a research center in the United States to conduct clinical trials for the FDA registration process for the BACTEROMIC system with the UNI FAST Panel. This is a key step in the US market entry strategy, with FDA certification planned for the extended UNI FAST version covering up to 52 antibiotics and 3 resistance mechanisms.
• SC ELTA 90 Medical Research SRL (ELTA MR)coreChannel Partner/ Reseller/ Distributor · 21 January 2026ELTA MR is an international company operating in Romania, Bulgaria, Serbia, and Greece, specializing in the supply and distribution of high-quality laboratory equipment, specialist consumables and tests, general laboratory consumables, reagents, and laboratory furniture. A distribution agreement was signed in January 2026 for distribution and promotion of the BACTEROMIC system in Romania. Registration of the BACTEROMIC system per local regulations is required before commencing distribution.
• MefamedcoreChannel Partner/ Reseller/ Distributor · 8 January 2026Mefamed is an experienced distributor of medical devices in Turkey, specializing in innovative technologies and working with international brands. A two-year framework distribution agreement was signed in January 2026 for the distribution and promotion of the BACTEROMIC system on the Turkish market. Distribution activities require local registration of the BACTEROMIC system per Turkish regulations.
• Clinical Advisory Board (Stefan Riedel, Stephen Kidd, Tiziana Di Martino, Scott O'Brien)coreStrategic or Co-development Partner · 23 October 2025Bacteromic established an international Clinical Advisory Board with experts from the UK, Italy, and the US: Stefan Riedel (Professor of Pathology, Harvard Medical School, Head of Clinical Microbiology at Beth Israel Deaconess Medical Center), Stephen Kidd (Clinical Scientist, Hampshire Hospitals NHS Foundation Trust, UK), Tiziana Di Martino (Physician and Manager with 20+ years in clinical practice, scientific research, and health economics), and Scott O'Brien (25+ years in global life sciences and diagnostics). The board supports the development of BACTEROMIC and its commercialization in international markets.
• FDA Certification AdvisorcoreImplementation/ SI/ Consulting Partner · 29 September 2025Scope Fluidics expanded its collaboration with a US-based advisor for the FDA certification process for the BACTEROMIC system with the UNI FAST Panel. The expanded scope allows Bacteromic to pursue certification for an extended FAST UNI version covering up to 52 antibiotics and 3 resistance mechanisms (ESBL, MR, HLGR). The clinical trials and reproducibility costs increased by approximately USD 1.3 million (from USD 2 million to USD 3.3 million). FDA certification is planned for H1 2027.
• Contract Research Organisation (CRO)coreImplementation/ SI/ Consulting Partner · 19 September 2025Bacteromic conducted clinical trials required for IVDR certification in collaboration with a Contract Research Organisation (CRO). Based on clinical trial results, Bacteromic submitted IVDR documentation to the notified body for the BACTEROMIC system with the UNI Panel (30 antibiotics, 56 drug-bug combinations, 1 ESBL resistance mechanism).

Scale indicators11 records

Recent moves9 records

Expansion highlights7 records

Broad incumbents

• bioMérieux: Global leader in microbiology diagnostics, including VITEK 2 — the dominant automated AST platform. Directly comparable to Scope Fluidics' BACTEROMIC as the incumbent AST standard against which BACTEROMIC must compete.
• Beckman Coulter (Danaher): Major diagnostic instrument manufacturer whose MicroScan system is a leading automated AST/bacterial identification platform used in hospital labs. Broad incumbent comparable to Scope Fluidics as both serve the hospital microbiology AST market.
• BD (Becton Dickinson): Global medical device and diagnostics company with the BD Phoenix M50 AST system and broad microbiology portfolio. Comparable to Scope Fluidics as a diversified incumbent competing in the same hospital microbiology AST category.
• Bruker: Diversified scientific instrument and diagnostics company with MALDI Biotyper for microbial identification and a growing microbiology portfolio. Broad incumbent comparable to Scope Fluidics in the clinical microbiology space.
• Bio-Rad Laboratories: Clinical diagnostics and life science research company that acquired Curiosity Diagnostics from Scope Fluidics in 2022 for ~$170M. Particularly relevant as the prior acquirer of a Scope Fluidics SPV and a potential strategic acquirer of BACTEROMIC.

Direct peers

• Accelerate Diagnostics: Commercial-stage rapid AST company (Accelerate Pheno system) targeting hospital microbiology labs with significantly faster time-to-result than traditional methods. Closely comparable to BACTEROMIC in product category, customer segment, and value proposition.
• Q-Linea: Swedish developer of ASTar, a rapid AST system for sepsis and bloodstream infections. Directly comparable to BACTEROMIC in target use case (rapid AST for bloodstream infections), customer (hospital microbiology labs), and product category.
• Selux Diagnostics: Boston-based rapid AST company developing next-generation phenotypic AST with same-day results. Closely comparable to BACTEROMIC in addressing faster antibiotic susceptibility determination for critical infections.
• Specific Diagnostics: Developer of the Reveal rapid AST system using proprietary biochemical sensors for same-day AST. Comparable to BACTEROMIC as a smaller, focused rapid-AST competitor targeting the same hospital microbiology workflow.

Emerging players

• T2 Biosystems: Developer of T2 Magnetic Resonance-based rapid diagnostics for sepsis-causing pathogens. Comparable emerging player to Scope Fluidics in rapid infectious disease diagnostics, though focused on molecular detection rather than phenotypic AST.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries4 records

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scope Fluidics